CN100349609C - Cirrhosis treating medicine - Google Patents
Cirrhosis treating medicine Download PDFInfo
- Publication number
- CN100349609C CN100349609C CNB2006100651686A CN200610065168A CN100349609C CN 100349609 C CN100349609 C CN 100349609C CN B2006100651686 A CNB2006100651686 A CN B2006100651686A CN 200610065168 A CN200610065168 A CN 200610065168A CN 100349609 C CN100349609 C CN 100349609C
- Authority
- CN
- China
- Prior art keywords
- polaprezinc
- chronic hepatitis
- medicine
- liver
- cirrhosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses medicine for inhibiting chronic hepatitis, hepatic fibrosis and hepatic cirrhosis, namely an inhibitor. The inhibitor uses polaprezinc as effective components.
Description
Technical field
The present invention is about the carrying out property hepatic fibrosis that suppresses the concurrent generation of chronic hepatitis and suppresses the medicine that develops to liver cirrhosis.
Technical background
The chronic hepatopathy that chronic hepatitis is mainly caused by hepatitis virus, acute viral hepatitis do not have hepatitis of curing and the hepatitis that same symptoms is arranged through treatment after a while.Viral chronic hepatitis has B (second) type chronic hepatitis and C (third) type chronic hepatitis etc.The cause of disease of chronic hepatitis also has ethanol, medicine, poisoning, liver fat liver, hepatolenticular degeneration, autoimmune hepatitis etc. except virus.
These chronic hepatitiss continue development and just become liver cirrhosis.The cause of disease of liver cirrhosis is that hepatocyte continues to change, and repairs by liver cell regeneration usually; But intensive, longer duration takes place in the hepatocyte obstacle, and inflammatory reaction repeatedly makes the interior fiber of liver increase hardening; Remaining hepatocyte regenerates strongly, makes and forms tuberosity in the liver.The compressing of this tuberosity is that the vascular system at center increases the weight of liver inner blood circulatory disturbance with the liver angular vein.Cause hepatic portal vein voltage rise height thus, hepatic blood flow minimizing etc. further increases the weight of the hepatocyte obstacle, produces vicious cycle.
Just produce hepatic fibrosis by such development of chronic hepatitis during to liver cirrhosis, become the liver cirrhosis of irreversible state by the chronic hepatitis of this reversible state.Therefore, the hepatic fibrosis medicines of the concurrent generation of inhibition carrying out property chronic hepatitis is very important as the chronic hepatitis treatment medicine.
Existing known chronic hepatitis treatment medicine has interferon, lamivudine and hepatoprotective etc.But interferon and lamivudine are antiviral agent, and hepatoprotective is the medicine that mainly the hepatocyte obstacle is had protective effect, and hepatic fibrosis is not had inhibitory action.
Polaprezinc (Polaprezinc) [L-carnosine (being β-alanyl-L one histidine) zincate; L-carnosine zincate] be known widely used already effective drug for peptic ulcer thing (1984-88270 communiques of Japan Patent), the liver function barrier that the oxyhepatitis model carbon tetrachloride is caused is (1988-No. 14728 communiques of Japan Patent) effectively.Yet polaprezinc is not understood fully to the mechanism of action of chronic hepatitis.
Summary of the invention
The purpose of this invention is to provide the medicine for the treatment of liver cirrhosis.
Therefore the present inventor uses and brings out the chronic hepatitis model of liver function barrier with known carbon tetrachloride and finish the sulfur acetamide model exploration hepatic fibrosis inhibition medicine that different mechanism of action produce hepatic insufficiency, having finished the present invention finds the medicative polaprezinc of liver cirrhosis (Polaprezinc) promptly be the invention provides the cirrhosis treating medicine that contains the effective ingredient polaprezinc.
Can significantly suppress the concurrent generation hepatic fibrosis of chronic hepatitis according to medicine of the present invention, so it can prevent that chronic hepatitis from developing to liver cirrhosis.
Medicine effective ingredient polaprezinc of the present invention is a L-carnosine zinc hydrochlorate, can use the aforementioned documents data:
(1) spy opens-No. 88270 communiques in clear 59 (1984)
(2) spy opens-No. 14728 communiques in clear 63 (1988)
(3) special fair 7 (nineteen ninety-five)-No. 116160 communiques
(4) preparation method of record such as-No. 5367 communiques in special fair 3 (1991) obtains.
Polaprezinc in the aftermentioned test example has good therapeutic effect to chronic hepatitis sulfur acetamide model, especially hydroxyproline (Hydroxyproline) amount and hyaluronic acid in the hepatic fibrosis marking tissue can be significantly reduced, and liver tissue fibrosis and the significant TGF-of reduction β amount can be suppressed significantly.(being that the back takes place chronic hepatitis) gives polaprezinc and can both obtain above-mentioned good therapeutic effect not only before the sulfur acetamide uses, and in the use of sulfur acetamide, and this point is very important.Therefore, polaprezinc is as cirrhosis treating medicine, and particularly the treatment as chronic hepatitis liver cirrhosis is useful.
As medicine of the present invention, the most handy oral preparation drug administration, particularly tablet, powder, granule, syrup and capsule etc. are the most suitable.
In these preparations are produced, can select for example water for injection of suitable adjuvant, Purified Water, carboxymethylcellulose calcium, sodium carboxymethyl cellulose, lactose, sorbitol, mannitol, white sugar, corn starch, crystalline cellulose, lactose, cellulose derivative, arabic gum, tragacanth mucilage, gelatin, Tween 80, Pulvis Talci, magnesium stearate, water, ethanol, white beeswax, glycerol, fat, fatty oil, glycols.Senior alcohols such as hard ester alcohol, liquid paraffin, paraffin, Apis cerana Fabricius, polyoxyethylene hardened castor oil, glucide, syrup etc. are used in combination.
Can be according to the age, body constitution, ill symptom, curative effect, medication, administration number of times and the course of treatment different take the circumstances into consideration to increase and decrease the dosage of polaprezinc.Adult's optimal dose is 1 0.01-10g.Preferably 1 day dosage is divided into 1-4 administration.
Description of drawings
Fig. 1 shows that polaprezinc is to organizing the influence of hydroxyproline amount.
Fig. 2 shows the influence of polaprezinc to transparency of organization matter acid amount.
Fig. 3 shows the influence of polaprezinc to tissue T GB-B1 amount.
Fig. 4 shows the hepatic tissue figure of polaprezinc to the hepatic fibrosis influence.Last figure is HE (hematoxylin and eosin) dyeing; Right figure is that sulfur acetamide+polaprezinc 500mg/kg group, left figure are 20 week of sulfur acetamide groups.Figure below is Sirius red colouring body: right figure is that sulfur acetamide+polaprezinc 500mg/kg group, left figure are 20 week of sulfur acetamide groups.
The specific embodiment
Enumerate following experimental example and illustrate in greater detail the present invention.But be not limited to this example.
Embodiment 1:
With rat grouping, 15 every group.300mg/L sulfur acetamide aqueous solution is organized the rat drinking water in contrast, drinks for 10 week or 20 weeks continuously.300mg/L sulfur acetamide aqueous solution drank for 20 weeks continuously also as experimental group rat drinking water, but at the 10th week back oral 200mg/day/kg of increase or 500mg/day/kg polaprezinc.
Matched group and experimental group rat kill them after giving medicine in accordance with regulations, take out liver.Measure label hyaluronic acid in the hepatic fibrosis serum with milk coagulation immunoturbidimetry.Chloramines and Paul Ehrlich solution absorption spectrphotometric method for measuring liver tissue fibrosis label hydroxyproline with the salt acid treatment.Measure promoting hepatic fibrosis that TGF-β 1 special role, that increase in the hepatic tissue is arranged with the ELISA method.Carrying out hepatic tissue dyeing is purpose Sirius red colouring, identifies the activation spider cell that fibrosis is played a major role with α-SMS immunostaining.In addition, with transferring enzyme and alkali phosphatase in the serum in the biology method measuring hepatopathy label.
These measurement results are shown among Fig. 1, Fig. 2, Fig. 3, Fig. 4 and the table 1.
Table 1
| Group | Serum levels of ALP (u/L) * |
| 10 weeks of sulfur acetamide are organized | 964±34 |
| 20 weeks of sulfur acetamide are organized | 1429±137 a |
| 20 weeks of sulfur acetamide+polaprezinc 200mg/kg group | 728±28 b |
| 20 weeks of sulfur acetamide+polaprezinc 500mg/kg group | 829±28 b |
| Matched group (non-administration group) | 525±26 c |
* ALP: alkali phosphatase
A:p＜0.01 (with matched group, sulfur acetamide 10 all groups, the sulfur acetamide+there were significant differences for the polaprezinc group)
B:p＜0.01 (there were significant differences with matched group)
C:p＜0.01 (significant difference being arranged) with sulfur acetamide 10 all groups, 20 all groups, sulfur acetamide+polaprezinc group.
Fig. 1, Fig. 2, Fig. 3, Fig. 4 show significantly: even just begin oral polaprezinc after the sulfur acetamide took for 10 weeks, but hepatic fibrosis label hydroxyproline amount, hyaluronic acid and TGF-B1 amount significantly reduce, as seen polaprezinc has obvious inhibitory action to liver tissue fibrosis, is useful as the liver tissue fibrosis inhibitor.In addition, table 1 also shows: hepatic insufficiency label alkali phosphatase (ALP) value has clear improvement, the chronic hepatitis symptom also has clear improvement.
Claims (2)
1. the purposes of polaprezinc in the medicine of preparation treatment liver cirrhosis.
2. the purposes of polaprezinc in the medicine of preparation treatment liver cirrhosis and chronic hepatitis hepatic fibrosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100651686A CN100349609C (en) | 2006-03-23 | 2006-03-23 | Cirrhosis treating medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100651686A CN100349609C (en) | 2006-03-23 | 2006-03-23 | Cirrhosis treating medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1857715A CN1857715A (en) | 2006-11-08 |
| CN100349609C true CN100349609C (en) | 2007-11-21 |
Family
ID=37296703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100651686A Expired - Fee Related CN100349609C (en) | 2006-03-23 | 2006-03-23 | Cirrhosis treating medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100349609C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022005848A1 (en) * | 2020-07-01 | 2022-01-06 | Nelson Deanna J | Combinations of carnosine and zinc for the treatment and prevention of viral infections |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103319413B (en) * | 2013-06-08 | 2015-02-04 | 西藏海思科药业集团股份有限公司 | Polaprezinc compound |
| CN104083751B (en) * | 2014-07-18 | 2016-08-24 | 大连大学 | A kind of medical composition and its use for cirrhosis treatment |
| CN107106602B (en) * | 2015-03-03 | 2021-03-23 | 谢灵均 | Hepatic fibrosis improving agent |
| CN106562976A (en) * | 2016-10-17 | 2017-04-19 | 吉林省博大伟业制药有限公司 | Application of polaprezinc in preparing medicines for treating colon cancer |
| CN110099690B (en) * | 2017-11-30 | 2021-10-26 | 北京通复堂生物科技股份有限公司 | Compound preparation suitable for treating non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis and/or hepatic steatosis |
| CN108310362A (en) * | 2018-02-05 | 2018-07-24 | 中国人民解放军第四五八医院 | Application of the carnosine in terms of hepatitis virus resisting |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6314728A (en) * | 1986-07-03 | 1988-01-21 | Zeria Shinyaku Kogyo Kk | Preventive and remedy for hepatic disorder |
| JP2001072588A (en) * | 1999-09-03 | 2001-03-21 | Hamari Chemicals Ltd | Therapeutic agent for muscular dystrophy |
| JP2002068981A (en) * | 2000-08-22 | 2002-03-08 | Hamari Chemicals Ltd | Medicament for ameliorating anorexia and dysgeusia of patient with late stage of cancer |
-
2006
- 2006-03-23 CN CNB2006100651686A patent/CN100349609C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6314728A (en) * | 1986-07-03 | 1988-01-21 | Zeria Shinyaku Kogyo Kk | Preventive and remedy for hepatic disorder |
| US4927817A (en) * | 1986-07-03 | 1990-05-22 | Zeria Pharmaceutical Co., Ltd. | Preventive and therapeutic agent against liver disorder |
| JP2001072588A (en) * | 1999-09-03 | 2001-03-21 | Hamari Chemicals Ltd | Therapeutic agent for muscular dystrophy |
| JP2002068981A (en) * | 2000-08-22 | 2002-03-08 | Hamari Chemicals Ltd | Medicament for ameliorating anorexia and dysgeusia of patient with late stage of cancer |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022005848A1 (en) * | 2020-07-01 | 2022-01-06 | Nelson Deanna J | Combinations of carnosine and zinc for the treatment and prevention of viral infections |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1857715A (en) | 2006-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100349609C (en) | Cirrhosis treating medicine | |
| JP6250588B2 (en) | Treatment of portal hypertension and repair of liver function using L-ornithine phenylacetate | |
| Kim et al. | Metformin-associated lactic acidosis: predisposing factors and outcome | |
| Kadikoylu et al. | Emergent therapy with therapeutic plasma exchange in acute recurrent pancreatitis due to severe hypertriglyceridemia | |
| Liu et al. | Neferine inhibits proliferation and collagen synthesis induced by high glucose in cardiac fibroblasts and reduces cardiac fibrosis in diabetic mice | |
| BR112021006002A2 (en) | compositions for the reduction of serum uric acid | |
| US20210379059A1 (en) | Combination of substances for regenerative therapy in patients with type 1 diabetes mellitus | |
| Sachs et al. | Medical implications of hyperuricemia | |
| TW527190B (en) | Pharmaceutical composition for treating acute renal failure caused by rhabdomyolysis, and for treating myoglobinuria | |
| WO2017121333A1 (en) | Use of cistanche tubulosa extract and isoacteoside in protection of muscles | |
| WO2023108905A1 (en) | Use of inosine in preparation of drug for treating coronavirus disease 2019 | |
| CN116098918A (en) | Citicoline pharmaceutical composition and application thereof | |
| CN110099690A (en) | Suitable for non-alcohol fatty liver (NAFLAD) and/or nonalcoholic fatty liver disease (NASH) and/or the compound preparation of adipohepatic treatment and prevention | |
| CN114949024A (en) | Herba Cephalanoploris total flavonoids, preparation method and application thereof in preparing medicine for preventing or treating hyperuricemia | |
| CN106822899B (en) | Medicine for promoting myocardial regeneration by inhibiting autophagy | |
| CN112807292A (en) | Application of bunge auriculate root benzophenone in preparation of uric acid reducing medicines | |
| CN105250368B (en) | It is a kind of to delay Chinese medicine composition of renal failure and its preparation method and application | |
| CN102836170B (en) | Hyperoxia compound glycine pyridoxal electrolyte injecta | |
| JP4802470B2 (en) | Liver fibrosis inhibitor | |
| WO2016139740A1 (en) | Hepatic fibrosis-ameliorating agent | |
| KR101647348B1 (en) | Composition for Preventing and Treating Gout Comprising Small Heterodimer Partner | |
| US4990513A (en) | Antihypoxic drug and method of its application | |
| CN117085006B (en) | Application of salvianolic acid Y in preparing medicament for treating urticaria | |
| JP4627580B2 (en) | Liver disease treatment | |
| Nagamatsu et al. | Antinephritic effects of PGE1 and Thiaprostaglandin E1, TEI-5178 and TEI-6122, on crescentic-type anti-GBM nephritis in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ENTEC PHARMACEUTICAL TECHNOLOGY ( BEIJING ) CO., Free format text: FORMER OWNER: ENTAIKE DIGITAL SCI-TECH (BEIJING) CO., LTD. Effective date: 20070209 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070209 Address after: 100005 room 26, news building, 631 Jianguomen Avenue, Beijing, Dongcheng District Applicant after: Entaike Digital Sci-Tech (Beijing) Co., Ltd. Address before: 100005, 11A, room 5, two office building, Dongfang economic and Trade City, Dongfang Plaza, Beijing, Dongcheng District Applicant before: Nteco digital technology (Beijing) Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090313 Address after: Tokyo, Japan, Japan Patentee after: AIF Limited by Share Ltd Address before: Room 26, news building, 631 Jianguomen Avenue, Dongcheng District, Beijing Patentee before: Entaike Digital Sci-Tech (Beijing) Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: AIF CO., LTD. Free format text: FORMER OWNER: ENTEC PHARMACEUTICAL TECHNOLOGY ( BEIJING ) CO., LTD. Effective date: 20090313 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071121 Termination date: 20180323 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |